Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone
Drug ID BADD_D02271
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00385
MeSH ID D014221
PubChem ID 31307
NDC Product Code 22552-0003; 46439-8701; 38779-0051; 51927-1049
Synonyms Triamcinolone | Volon | Aristocort
Chemical Information
Molecular Formula C21H27FO6
CAS Registry Number 124-94-7
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Malignant melanomaSerotransferrinP02787T026173015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
Malignant melanomaInsulinP01308T828413015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abscess11.01.08.0010.000190%Not Available
Acne23.02.01.0010.000253%Not Available
Alkalosis hypokalaemic14.01.02.002--Not Available
Anaphylactic shock24.06.02.004; Available
Anaphylactoid reaction24.06.03.007; Available
Angioedema23.04.01.001; Available
Application site reaction12.07.01.006; Available
Arrhythmia02.03.02.001--Not Available
Arthropathy15.01.01.0030.000126%Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; Available
Atrophy08.03.04.0010.000379%Not Available
Back pain15.03.04.005--
Benign intracranial hypertension17.07.02.001--Not Available
Blindness17.17.01.003; Available
Blister23.03.01.001; Available
Blood cortisol decreased13.10.09.004--Not Available
Blood glucose decreased13.02.02.0010.000126%Not Available
Blood glucose increased13.02.02.0020.000190%Not Available
Blood pressure increased13.14.03.0050.000569%Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages